-
Product Insights
NewNet Present Value Model: Achilles Therapeutics Plc’s ATL-001
Empower your strategies with our Net Present Value Model: Achilles Therapeutics Plc's ATL-001 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – NGI-226 in Tendon and Ligament Pain
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NGI-226 in Tendon and Ligament Pain report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NGI-226 in Tendon and Ligament Pain Drug Details: NGI-226 is...
-
Sector Analysis
Soft Tissue Biologics Market Size by Segments, Share, Regulatory, Reimbursement, Procedures and Forecast to 2033
Soft Tissue Biologics Market Report Overview The Soft Tissue Biologics market size was $361.1 Million in 2023. The market is expected to grow at a CAGR of more than 2% during 2023-2033. Soft Tissue Biologics are used in surgical procedures to replace, reinforce, or repair tendons or ligaments that have been torn or damaged in the human body. The market focuses on the repair of the anterior cruciate ligament (ACL), posterior cruciate ligament (PCL), rotator cuff, and Achilles tendon. Soft...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – JAB-2485 in Triple-Negative Breast Cancer (TNBC)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. JAB-2485 in Triple-Negative Breast Cancer (TNBC) Drug Details: JAB-2485 is under development for the treatment...
-
Product Insights
Malaria – Drugs In Development, 2023
Global Markets Direct’s, ‘Malaria - Drugs In Development, 2023’, provides an overview of the Malaria pipeline landscape. The report provides comprehensive information on the therapeutics under development for Malaria, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ATL-001 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ATL-001 in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ATL-001 in Non-Small Cell Lung Cancer Drug Details: ATL-001 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ATL-001 in Metastatic Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ATL-001 in Metastatic Melanoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ATL-001 in Metastatic Melanoma Drug Details: ATL-001 is under development for the...
-
Product Insights
Collagens Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies
Collagens Pipeline Market Report Overview Collagen dressings are typically made up of a combination of animal collagen and any other formulation for structural integrity, and sodium or calcium ions. These are available in many forms such as sheets, gels, pads, particles, and pastes. The Collagens pipeline market research report provides a comprehensive understanding of the pipeline products along with their comparative analysis at various stages of development. The report also includes information about the territories wherein the clinical trials are...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ATL-001 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ATL-001 in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.ATL-001 in Non-Small Cell Lung Cancer Drug Details:ATL-001 is under development...